中源协和：关于全资子公司药品临床试验申请取得受理通知书的公告

Core Viewpoint - Zhongyuan Union announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) on August 1, 2025 [1] Group 1 - The clinical trial application for VUM02 injection has been officially accepted by the NMPA [1]